Lysophosphatidic acid causes endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells

Atherosclerosis

Volumn 222, Issue 1, 2012, Pages 74-83

  Chen, Chanygi ^a   Ochoa, Lyssa N ^a   Kagan, Anna ^a   Chai, Hong ^a   Liang, Zhengdong ^a   Lin, Peter H ^a   Yao, Qizhi ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Endothelial cells; Endothelial dysfunction; ENOS; Lysophosphatidic acid; Selenomethionine; Superoxide anion; Vasorelaxation

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LYSOPHOSPHATIDIC ACID; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; SELENOMETHIONINE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; ENDOTHELIAL DYSFUNCTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOREACTIVITY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWINE; VASODILATATION; VASOMOTOR REFLEX;

ANIMALS; ATHEROSCLEROSIS; BRADYKININ; CORONARY VESSELS; DOWN-REGULATION; ENDOTHELIUM, VASCULAR; HUMANS; LYSOPHOSPHOLIPIDS; MEMBRANE POTENTIAL, MITOCHONDRIAL; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; SELENOMETHIONINE; SUPEROXIDE DISMUTASE; SUPEROXIDES; SWINE; VASODILATION;

EID: 84862792752     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.02.010     Document Type: Article

References (52)

1. Gaits F., Fourcade O., Le Balle F., et al. Lysophosphatidic acid as a phospholipid mediator: pathways of synthesis. FEBS Lett 1997, 410:54-58.
2. Fourcade O., Simon M.F., Viodé C., et al. Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell 1995, 80:919-927.
3. Lee H., Liao J.J., Graeler M., et al. Lysophospholipid regulation of mononuclear phagocytes. Biochim Biophys Acta 2002, 1582:175-177.
4. Xie Y., Gibbs T.C., Mukhin Y.V., Meier K.E. Role for 18:1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells. J Biol Chem 2002, 277:32516-32526.
5. Weiner J.A., Fukushima N., Contos J.J., et al. Regulation of Schwann cell morphology and adhesion by receptor-mediated lysophosphatidic acid signaling. J Neurosci 2001, 21:7069-7078.
6. Pages C., Simon M., Valet P., Saulnier-Blache J.S. Lysophosphatidic acid synthesis and release (1). Prostaglandins 2001, 64:1-10.
7. Xie Y., Gibbs T.C., Meier K.E. Lysophosphatidic acid as an autocrine and paracrine mediator. Biochim Biophys Acta 2002, 1582:270-281.
8. Siess W., Zangl K.J., Essler M., et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci U S A 1999, 96:6931-6936.
9. Rother E., Brandl R., Baker D.L., et al. Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation 2003, 108:741-747.
10. ler M., Amano M., Kruse H.J., et al. Thrombin inactivates myosin light chain phosphatase via Rho and its target Rho kinase in human endothelial cells. J Biol Chem 1998, 273:21867-21874.
11. Colangelo S., Langille B.L., Steiner G., Gotlieb A.I. Alterations in endothelial F-actin microfilaments in rabbit aorta in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998, 18:52-56.
12. Haserück N., Erl W., Pandey D., et al. The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors. Blood 2004, 103:2585-2592.
13. Yoshida K., Nishida W., Hayashi K., et al. Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo. Circulation 2003, 108:1746-1752.
14. Siess W. Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim Biophys Acta 2002, 1582:204-215.
15. Noguchi K., Herr D., Mutoh T., Chun J. Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol 2009, 9:15-23.
16. Quyyumi A.A. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 1998, 105:32S-39S.
17. Teo S.T., Yung Y.C., Herr D.R., Chun J. Lysophosphatidic acid in vascular development and disease. IUBMB Life 2009, 61:791-799.
18. Smyth S.S., Cheng H.Y., Miriyala S., et al. Roles of lysophosphatidic acid in cardiovascular physiology and disease. Biochim Biophys Acta 2008, 1781:563-570.
19. van Nieuw Amerongen G.P., Vermeer M.A., van Hinsbergh V.W. Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler Thromb Vasc Biol 2000, 20:E127-E133.
20. Avraamides C., Bromberg M.E., Gaughan J.P., et al. Hic-5 promotes endothelial cell migration to lysophosphatidic acid. Am J Physiol Heart Circ Physiol 2007, 293:H193-H203.
21. Panetti T.S., Nowlen J., Mosher D.F. Sphingosine-1-phosphate and lysophosphatidic acid stimulate endothelial cell migration. Arterioscler Thromb Vasc Biol 2000, 20:1013-1019.
22. Neidlinger N.A., Larkin S.K., Bhagat A., et al. Hydrolysis of phosphatidylserine-exposing red blood cells by secretory phospholipase A2 generates lysophosphatidic acid and results in vascular dysfunction. J Biol Chem 2006, 281:775-781.
23. Lin C.I., Chen C.N., Chen J.H., Lee H. Lysophospholipids increase IL-8 and MCP-1 expressions in human umbilical cord vein endothelial cells through an IL-1-dependent mechanism. J Cell Biochem 2006, 99:1216-1232.
24. Gustin C., Delaive E., Dieu M., et al. Upregulation of pentraxin-3 in human endothelial cells after lysophosphatidic acid exposure. Arterioscler Thromb Vasc Biol 2008, 28:491-497.
25. Rizza C., Leitinger N., Yue J., et al. Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction. Lab Invest 1999, 79:1227-1235.
26. Lin L.I., Chen C.N., Lin P.W., et al. Lysophosphatidic acid regulates inflammation-related genes in human endothelial cells through LPA1 and LPA3. Biochem Biophys Res Commun 2007, 363:1001-1008.
27. Nakanaga K., Hama K., Aoki J. Autotaxin-an LPA producing enzyme with diverse functions. J Biochem 2010, 148:13-24.
28. Im E., Motiejunaite R., Aranda J., et al. PLC-γ activation drives increased production of autotaxin in endothelial cells and LPA-dependent regression. Mol Cell Biol 2010, 30:2401-2410.
29. Wu H.L., Lin C.I., Huang Y.L., et al. Lysophosphatidic acid stimulates thrombomodulin lectin-like domain shedding in human endothelial cells. Biochem Biophys Res Commun 2008, 367:162-168.
30. Landmesser U., Hornig B., Drexler H. Endothelial function. A critical determinant in atherosclerosis?. Circulation 2004, 109S:II:27-33.
31. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000, 87:840-844.
32. Chen C., Chai H., Wang X., et al. Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells. Blood 2008, 112:3205-3216.
33. Wang X., Chai H., Lin P., et al. Roles and mechanisms of HIV protease inhibitor ritonavir and other anti-HIV drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells. Am J Pathol 2009, 174:771-781.
34. Nino E. Phospholipid mediators in the vessel wall: involvement in atherosclerosis. Curr Opin Clin Nutr Metab Care 2005, 8:123-131.
35. Eichholtz T., Jalink K., Fahrenfort I., Moolenaar W.H. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 1993, 291:677-680.
36. Xu Y.J., Aziz O.A., Bhugra P., et al. Potential role of lysophosphatidic acid in hypertension and atherosclerosis. Can J Cardiol 2003, 19:1525-1536.
37. Kou R., Igarashi J., Michel T. Lysophosphatidic acid and receptor-mediated activation of endothelial nitric-oxide synthase. Biochemistry 2002, 41:4982-4988.
38. Igarashi J., Bernier S.G., Michel T. Sphingosine 1-phosphate and activation of endothelial nitric-oxide synthase. Differential regulation of Akt and MAP kinase pathways by EDG and bradykinin receptors in vascular endothelial cells. J Biol Chem 2001, 276:12420-12426.
39. Llodrá J., Angeli V., Liu J., et al. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci U S A 2004, 101:11779-11784.
40. Damirin A., Tomura H., Komachi M., et al. Role of lipoprotein-associated lysophospholipids in migratory activity of coronary artery smooth muscle cells. Am J Physiol Heart Circ Physiol 2007, 292:H2513-H2522.
41. Hayashi K., Takahashi M., Nishida W., et al. Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids. Circ Res 2001, 89:251-258.
42. Siess W., Tigyi G. Thrombogenic and atherogenic activities of lysophosphatidic acid. J Cell Biochem 2004, 92:1086-1094.
43. Zhou Z., Subramanian P., Sevilmis G., et al. Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab 2011, 13:592-600.
44. Bot M., Bot I., Lopez-Vales R., et al. Atherosclerotic lesion progression changes lysophosphatidic acid homeostasis to favor its accumulation. Am J Pathol 2010, 176:3073-3084.
45. Tigyi G., Hong L., Yakubu M., et al. Lysophosphatidic acid alters cerebrovascular reactivity in piglets. Am J Physiol 1995, 268:H2048-H2055.
46. Tokumura A., Fukuzawa K., Tsukatani H. Effects of synthetic and natural lysophosphatidic acids on the arterial blood pressure of different animal species. Lipids 1978, 13:572-574.
47. Zhang C., Baker D.L., Yasuda S., et al. Lysophosphatidic acid induces neointima formation through PPARgamma activation. J ExpMed 2004, 199:763-774.
48. Wassmann S., Wassmann K., Nickening G. Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension 2004, 44:381-386.
49. Kaneyuki U., Ueda S., Yamagishi S., et al. Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation. Vascul Pharmacol 2007, 46:286-292.
50. Niu J., Profirovic J., Pan H., et al. G Protein betagamma subunits stimulate p114RhoGEF, a guanine nucleotide exchange factor for RhoA and Rac1: regulation of cell shape and reactive oxygen species production. Circ Res 2003, 93:848-856.
51. Chang C.L., Lin M.E., Hsu H.Y., et al. Lysophosphatidic acid-induced interleukin-1 beta expression is mediated through Gi/Rho and the generation of reactive oxygen species in macrophages. J Biomed Sci 2008, 15:357-363.
52. Letavayova L., Vlckova V., Brozmanova J. Selenium: from cancer prevention to DNA damage. Toxicology 2006, 227:1-14.